OBJECTIVE: To probe into the therapeutic effect of clopidogrel bisulfate combined with trimetazidine on coronary heart disease and its effects on oxidative stress response. METHODS: Totally 100 patients with coronary heart disease admitted into Shanghai Public Health Clinical Center from Jan. 2017 to Jan. 2019 were extracted to be divided into the trimetazidine group and the combined treatment group via the random number table

with 50 cases in each group. The trimetazidine group was treated with trimetazidine

while the combined treatment group received clopidogrel bisulfate on the basis of the trimetazidine group. Downward movement of ST segment

number of angina pectoris

duration of angina pectoris

disease control time

cardiac function [left ventricular end diastolic diameter（ LVEDD）

left ventricular end systolic diameter（ LVESD） and left ventricular ejection fraction（ LVEF） ]

platelet function

oxidative stress response

endothelial function

clinical efficacy and adverse drug reactions of two groups were observed. RESULTS: The disease control time in the combined treatment group was significantly shorter than that in the trimetazidine group

and the difference was statistically significant（ P < 0. 05）. After treatment

downward movement of ST segment in the combined treatment group was significantly lower than that in the trimetazidine group

the number of angina attack was significantly less than that in the trimetazidine group

and the duration of angina pectoris was significantly shorter than that in the trimetazidine group

with statistically significant difference（ P < 0. 05）. After treatment

LVEDD

LVESD

platelet aggregation rate and platelet response index of the combined treatment group were significantly lower than those of the trimetazidine group

and LVEF was significantly higher than that of the trimetazidine group

the differences were statistically significant（ P < 0. 05）. After treatment

the levels of MDA and ET-1 in the combined treatment group were significantly lower than those in the trimetazidine group

and the levels of SOD and NO were significantly higher than those in the trimetazidine group

the differences were statistically significant（ P < 0. 05）.The total effective rate of treatment in the combined treatment group was 94. 00%（ 47/50）

significantly higher than80. 00%（ 40/50） in the trimetazidine group

and the difference was statistically significant（ P < 0. 05）. The incidence of adverse drug reactions in the combined treatment group was 6. 00%（ 3/50）

higher than 4. 00%（ 2/50） in the trimetazidine group

the difference was not statistically significant（ P > 0. 05）. CONCLUSIONS: Clopidogrel hydrogen sulfate combined with trimetazidine can improve the clinical symptoms of patients with coronary heart disease

relieve the oxidative stress response and improve the endothelial function

with significant effects.